Lilly Outlook For Rx: Political Pressure Will Stay, So Will Double-Digit Growth
Executive Summary
Lilly is preparing investors for a prolonged period of pressure on prices and intellectual property - with the reassurance that they can still expect double-digit annual growth from the drug industry
You may also be interested in...
Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay
Merck expects Congress to pass reimportation legislation in 2003 but to retain the requirement that HHS certify the safety of the program before it is implemented
Reimportation Likely In 2003, Merck Says, But HHS Certification Should Stay
Merck expects Congress to pass reimportation legislation in 2003 but to retain the requirement that HHS certify the safety of the program before it is implemented
Lilly Zyprexa Strategies Include Medicaid Disease Management
Lilly is using a schizophrenia disease management program in Colorado as a pilot program to demonstrate that careful patient management can save states more money than supplemental rebates